Skip to main content

Table 3 Treatment phase indicators

From: Multicentre clinical radiotherapy audit in rectal cancer: results of the IROCA project

INDICATORS

ICO-B

ICO-G

ICO H

IPO

NO

WCO

All

 

N

(%)

N

(%)

N

(%)

N

(%)

N

(%)

N

(%)

N

%

P

Patients included in clinical trial

3

(7.5)

0

(0.0)

10

(25.0)

0

(0.0)

1

(4.5)

0

(0.0)

14

6.3

0.000

Long Course Radiotherapy (LCRT)

33

(82.5)

40

(100)

32

(80.0)

31

(79.5)

11

(50.0)

24

(60.0)

171

77.4

0.000

Short Course Radiotherapy (SCRT)

7

(17.5)

0

(0.0)

8

(20.0)

8

(20.5)

11

(50.0)

16

(40.0)

50

22.6

0.000

3DCRT

32

(80.0)

40

(100)

29

(72.5)

4

(10.3)

0

(0.0)

39

(97.5)

144

65.1

0.000

VMAT

8

(20.0)

0

(0.0)

11

(27.5)

2

(5.1)

6

(27.3)

1

(2.5)

28

12.7

0.000

IMRT

0

(0.0)

0

(0.0)

0

(0.0)

33

(84.6)

16

(72.7)

0

(0.0)

49

22.2

0.000

SIB

0

(0.0)

9

(22.5)

10

(25.0)

1

(2.6)

0

(0.0)

1

(2.5)

21

9.5

0.000

Treatment completed in prescription time

20

(50.0)

4

(10.0)

10

(25.0)

36

(92.3)

14

(63.6)

39

(97.5)

123

55.7

0.000

RT treatment interruption

20

(50.0)

36

(90.0)

29

(72.5)

3

(7.7)

8

(36.4)

1

(2.5)

97

43.9

0.000

Treatment interruption: patient reason

4

(20.0)

2

(5.6)

1

(3.4)

0

(0.0)

4

(50.0)

1

(100.0)

12

12.4

0.000

Treatment interruption: center-related

17

(85.0)

35

(97.2)

28

(96.6)

3

(100.0)

5

(62.5)

0

(0.0)

88

90.7

0.001

Treatment compensation for interruptions

0

(0.0)

1

(2.8)

0

(0.0)

0

(0.0)

0

(0.0)

1

(100.0)

2

2.1

0.000

Presented to 2nd MTB

18

(45.0)

20

(50.0)

22

(55.0)

3

(7.7)

1

(4.5)

3

(7.5)

67

30.3

0.000

Restaging MRI

10

(25.0)

28

(70.0)

18

(45.0)

0

(0.0)

8

(36.4)

37

(92.5)

101

45.7

0.000

Restaging TNM

4

(10.0)

20

(50.0)

9

(22.5)

0

(0.0)

0

(0.0)

29

(72.5)

62

28.1

0.000

Presented to MTB after surgery

2

(5.0)

23

(57.5)

30

(75.0)

28

(71.8)

5

(22.7)

39

(97.5)

127

57.5

0.000